BiotechTube

ONO-2910 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

CIPN - Chemotherapy-Induced Peripheral Neuropathy

Conditions

CIPN - Chemotherapy-Induced Peripheral Neuropathy

Trial Timeline

Aug 31, 2023 → Sep 19, 2024

NCT ID
NCT06538272

About ONO-2910 + Placebo

ONO-2910 + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for CIPN - Chemotherapy-Induced Peripheral Neuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT06538272. Target conditions include CIPN - Chemotherapy-Induced Peripheral Neuropathy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06538272Phase 2Completed

Competing Products

2 competing products in CIPN - Chemotherapy-Induced Peripheral Neuropathy

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
AK135AkesoPhase 1
32

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77